Dr. Lingvay is a clinical investigator in the field of diabetes, obesity, and associated metabolic complications. She leads an active clinical research program in the Division of Endocrinology at University of Texas Southwestern Medical Center in Dallas. Her research interests span from pathophysiology to finding new treatment options to improve the lives of patients with such conditions. Dr. Lingvay graduated from medical school among the top 5% of her class. She completed the Internal Medicine Residency at Texas Tech University in 2002, and Endocrinology, Diabetes and Metabolism Fellowship at University of Texas Southwestern Medical Center in 2005. Dr. Lingvay was selected to participate in the first class of the Clinical Research Scholars Program at UT Southwestern which she completed in 2008. In 2007 she received a National Institute of Health Career Development Award to study the role of pancreatic triglyceride accumulation in beta-cell failure and type 2 diabetes and to further develop her career as a clinical investigator. Dr. Lingvay also received the master's in Public Health degree from University of Texas School of Public Health in Houston in 2006. She has published her work in many renowned journals like JAMA New England Journal of Medicine, Lancet, Circulation, and Diabetes Care. She has contributed to many textbooks in the field of diabetes and is on the editorial board of several journals. Dr. Lingvay has been invited to present lectures to her peers all over the world. She is an active member of American Diabetes Association and has served on the scientific sessions organizing committee from 2016 to 2019.


Medical School
Carol Davila University of Medicine & Pharmacy (1998)
Texas Tech University Health Sciences Center (2002), Internal Medicine
UT Southwestern Medical Center (2005), Endocrinology & Metabolism
Graduate School
University of Texas Health Science Center at Houston (2006), Public Health
Other Post Graduate Training
University of Texas Health Science Center at Houston (2006)
Graduate School
UT Southwestern Medical Center (2008), Clinical Research
Other Post Graduate Training
UT Southwestern Medical Center (2008)

Research Interest

  • Metabolic Syndrome
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)
  • Obesity
  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus


Featured Publications LegendFeatured Publications

Lingvay I, Handelsman Y, Linjawi S, Vilsbøll T, Halladin N, Ranc K, Liebl A Endocr Pract 2018 Nov
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR Diabetes Care 2018 Jul
Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
Lingvay I, Leiter LA Circulation 2018 May 137 21 2200-2202
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomised, controlled trial.
Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P J. Clin. Endocrinol. Metab. 2018 Apr
Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.
Pop LM, Mari A, Zhao TJ, Mitchell L, Burgess S, Li X, Adams-Huet B, Lingvay I Diabetes Obes Metab 2018 Mar
Metabolic response 4 years after gastric bypass in a complete cohort with type 2 diabetes mellitus.
Gisella Carranza-Leon B, Puzziferri N, Adams-Huet B, Jabbour I, Lingvay I Diabetes Res. Clin. Pract. 2018 Jan
When Metformin Is Not Enough: Pros and Cons of SGLT2 and DPP-4 Inhibitors as a Second Line Therapy.
Avogaro A, Delgado E, Lingvay I Diabetes Metab. Res. Rev. 2018 Jan
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A Lancet Diabetes Endocrinol 2018 Jan
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR Diabetes Care 2017 Dec
Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy.
Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, Helmark IC, Wijayasinghe N, Larsen M Diabetes Obes Metab 2017 Nov


Featured Books Legend Featured Books

Secondary Forms of Diabetes Mellitus. In American College of Physicians- Medicine

Lingvay I, Raskin P (2006). American College of Physicians

Non-insulin Pharmacological Therapies. In Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management

Lingvay I, Rhee C, Raskin P (2006).

Honors & Awards

  • Jean W. Wilson Award for Scientific Mentorship
  • Jean W. Wilson Award for Scientific Mentorship

Professional Associations/Affiliations

  • American Diabetes Association
  • American Federation for Medical Research
  • European Association for the Study of Diabetes
  • The Endocrine Society